Connecticut lawmakers are getting ahead of the curve—again.
The state Senate has approved a bill to expand its existing psychedelic-assisted therapy pilot program, signaling a major shift toward broader access to treatments involving substances like psilocybin and MDMA.
Originally limited to specific groups like veterans and first responders, the updated proposal would open the program to any adults who meet clinical eligibility standards set by researchers.
The move is all about timing. Lawmakers are positioning Connecticut to act fast if—and when—the FDA gives the green light to psychedelic therapies. Instead of scrambling later, the state is laying the groundwork now.
Notably, the bill also removes language that would have automatically ended the program upon federal approval, signaling that Connecticut wants long-term involvement in the psychedelic treatment space—not just a temporary experiment.
Bottom line: Connecticut isn’t waiting for federal permission to start preparing—it’s building the system now so it can flip the switch the moment psychedelics go mainstream.
Dabbin-Dad Newsroom
